Companies Cryptocurrencies
Aprea Therapeutics Inc
Aprea Therapeutics Inc
Exchange: NasdaqGS
IPO Date: 03/10/2019
CEO: Mr. Christian S. Schade
Biotechnology Healthcare 🔗
  • APRE
  • 0.95
  • 22227340
    market cap
  • -0.03860003
If you bought

shares of Aprea Therapeutics Inc (APRE) on
You would have made
Old Price $12 Current Price $12

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The firm is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.

Address: 535 Boylston St Boston MASSACHUSETTS 02116

Stay updated.